British Business Bank Invests Record £75M in SV Health

The British Business Bank has announced a landmark investment in the biotech arena by committing £75 million to SV Health Investors’ latest fund. This substantial contribution, the largest in the bank’s history, is set to bolster the SV8 Biotech Fund, dedicated to advancements in therapeutics technology. Such a commitment underscores the growing focus on supporting UK life sciences, crucial for addressing significant clinical needs and fostering industry growth.

SV Health Investors is a prominent player in the UK’s health tech landscape, known for nurturing scientific endeavors into thriving companies. Their recent focus has spotlighted Cambridge-based biotech firm Artios, with a significant investment made just last month. Through this partnership, the British Business Bank has committed a total of £560 million across 15 life sciences funds, highlighting its dedication to strengthening the biotechnology ecosystem in the UK. According to Leandros Kalisperas, chief investment officer at the British Business Bank, this move not only aids top-performing companies in accessing vital growth-stage funding but also encourages other investors to follow suit. 

This record commitment by the British Business Bank signals a pivotal moment for the UK biotech sector, providing much-needed financial backing for innovation in therapeutics. Nikola Trbovic of SV Health Investors appreciates the bank’s ongoing support, which has been instrumental in turning groundbreaking science into impactful patient solutions. Through this partnership, the future looks promising for UK biotechnology.